2023 World Conference on Lung Cancer (Posters)-EP08.02. The Value of Combined Immunotherapy in Neoadjuvant Regimen for Patients with Resectable Non-small Cell Lung Cancer

EP08.02. The Value of Combined Immunotherapy in Neoadjuvant Regimen for Patients with Resectable Non-small Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

This abstract discusses the value of combining immunotherapy with neoadjuvant therapy in patients with resectable non-small cell lung cancer (NSCLC). The study aimed to determine the prognostic value of this combination therapy and identify the optimal treatment regimen. <br /><br />The study included 214 patients who underwent neoadjuvant immunochemotherapy or platinum-containing chemotherapy followed by surgery. Recurrence patterns, recurrence-free survival (RFS), and overall survival (OS) were compared between the two regimens. <br /><br />The results showed that patients treated with immunotherapy and chemotherapy had similar rates of complete resection (R0) and postoperative death within 30 days. However, the combination group had significantly higher rates of major pathological response (MPR) and pathologic complete response (pCR). <br /><br />When analyzing recurrence and survival in 194 patients, it was found that immunochemotherapy was associated with better RFS and OS compared to chemotherapy alone. Patients receiving chemotherapy alone had higher recurrence rates, especially distant or complex recurrence, which was associated with poorer OS. <br /><br />The study also found that MPR was associated with improved RFS and OS. Although MPR was not reached in all patients, those receiving immunochemotherapy had potentially better RFS and OS. Additionally, patients who did not achieve MPR could benefit from adjuvant therapy. <br /><br />In conclusion, combining immunotherapy with neoadjuvant therapy in patients with resectable NSCLC resulted in better pathological response, lower recurrence rates, and more limited recurrence compared to chemotherapy alone. Even in cases where complete pathological response was not achieved, the combination therapy showed potential for prolonged RFS and OS.

Asset Subtitle

Yu Tian

Meta Tag

Speaker Yu Tian

Topic Local-Regional NSCLC: Multimodality Therapy

Keywords

immunotherapy

neoadjuvant therapy

non-small cell lung cancer

prognostic value

treatment regimen

recurrence patterns

complete resection

pathologic complete response

chemotherapy

adjuvant therapy